Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
urinary-derived human chorionic gonadotropin + epidermal growth factor
- Development stage
- Phase 1
- Lead developer
- University of Minnesota
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Urinary-derived human chorionic gonadotropin + epidermal growth factor (uhCG/EGF) is a biologic combination therapy derived from human pregnancy urine. While human chorionic gonadotropin (hCG) is the primary component (often associated with the brand Pregnyl), the urinary-derived preparation naturally contains epidermal growth factor (EGF). The combination is being repurposed for the treatment and prophylaxis of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation. Its mechanism of action is dual: hCG acts as an immunomodulator to induce immune tolerance (mimicking the maternal-fetal environment), while EGF promotes the repair of the intestinal epithelial barrier by activating the EGFR pathway. The program has received Orphan Drug Designation from the FDA and has been evaluated in Phase I and Phase II clinical trials.
- Brand names
- Pregnyl
- Other names
- urinary human chorionic gonadotropin and epidermal growth factorhCG/EGF
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TSHR (Thyroid-stimulating hormone receptor)
Beyond the preview
Go deeper on urinary-derived human chorionic gonadotropin + epidermal growth factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on urinary-derived human chorionic gonadotropin + epidermal growth factor.